Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
破解密碼：了解拜瑪林製藥的分析師評論
9 analysts have expressed a variety of opinions on Biomarin Pharmaceutical (NASDAQ:BMRN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
過去一個季度，有9位分析師就拜瑪林製藥（納斯達克:BMRN）發表了各種不同的觀點，從看好到看淡不一。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近評級的精簡視圖，顯示了過去30天的不同情緒，並將其與前幾個月進行比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $99.67, a high estimate of $115.00, and a low estimate of $72.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.2%.
分析師評估的12個月目標價格揭示了更多見解，平均目標爲99.67美元，最高估價爲115.00美元，最低估價爲72.00美元。顯而易見的是，情緒出現了負面轉變，因爲分析師已將平均目標價格下調了1.2%。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
In examining...
通過...
登入免費觀看全文
登入/註冊